Skip to main content

US Army Will Use Metabolon Technology to Study Anthrax Vaccine in Humans

NEW YORK (GenomeWeb News) — Metabolon said yesterday that the US Army Medical Research Institute of Infectious Diseases will use its metabolomics platform to study the effects of the AVA anthrax vaccine in humans.
 
Metabolon's chief science officer Mike Milburn said the collaboration on the FDA-approved vaccine is the “first large-scale metabolomics study of human subjects given a vaccine.”
 
"This type of comprehensive biochemical profiling will help USAMRIID better understand the vaccine's safety, efficacy, and mechanism of action," Milburn added.
 
Metabolon’s technology performs in drug studies by measuring the spectrum of biochemical changes and maps them to metabolic pathways, the company said.
 
Financial terms of the agreement were not released.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.